AbbVie has settled its patent litigation with every generic manufacturer trying to launch a copy of Rinvoq in the United States, and the AbbVie Rinvoq settlement keeps generic upadacitinib off the U.S. market until April 2037. That is roughly four years longer than Wall Street had been pricing in. Shares jumped about 4% on the September 11, 2025 announcement, closing at a record $220.22.1Yahoo Finance. AbbVie Inc Historical Data2Reuters. AbbVie Shares Hit Record High as Key Immunology Drug Set for Exclusivity Until 2037
What the Settlement Does
AbbVie disclosed the deal in a Form 8-K filed with the SEC on September 11, 2025. The filing said the company had reached settlement and license agreements with every generic manufacturer that had filed an abbreviated new drug application for generic Rinvoq. Assuming pediatric exclusivity is granted, no generic version of upadacitinib tablets is expected to reach the U.S. market before April 2037.3SEC. AbbVie Inc Form 8-K
Five generic makers are covered: Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals, and Sun Pharmaceutical Industries. AbbVie had sued all five in the U.S. District Court for the District of Delaware in late 2023, alleging their ANDA filings infringed dozens of Rinvoq patents.4Fierce Pharma. AbbVie Settles With Generic Rinvoq Hopefuls, Shielding Immunology Blockbusters US Sales Until 20375Law360. AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037
Sandoz settled first. A stipulation filed on April 11, 2025 before Delaware District Judge Maryellen Noreika dismissed the case without prejudice, with Sandoz admitting that its proposed generic infringed 23 of AbbVie’s Rinvoq patents.6Law360. AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics The remaining four followed in September.
Why April 2037 Is the Number That Matters
Rinvoq’s composition-of-matter patent, which covers the molecule itself, expires in 2033. Most analysts had used that date as the working assumption for when generics could enter. But AbbVie’s Orange Book listings for Rinvoq include many additional patents covering manufacturing processes, solid-state forms, and methods of treating specific diseases, and some of those method-of-use patents run until March 2038.4Fierce Pharma. AbbVie Settles With Generic Rinvoq Hopefuls, Shielding Immunology Blockbusters US Sales Until 20377Drugs.com. Generic Rinvoq Availability
April 2037 splits the difference. AbbVie gets four additional years of exclusivity beyond the 2033 date the market had modeled. The generic companies get roughly a one-year head start on the latest-expiring patents rather than fighting them out in court.
What the Extra Four Years Mean for AbbVie
Rinvoq’s importance to AbbVie is easier to see against the Humira transition. When Humira lost U.S. exclusivity in early 2023, AbbVie’s sales of what had been the world’s best-selling drug dropped 32% that year, dragging total company revenue down 7%.8Clinical Trials Arena. AbbVie Counts on Skyrizi and Rinvoq to Fill Humira-Sized Hole The company had built up two newer immunology drugs, Skyrizi and Rinvoq, to absorb that loss.
The plan is working. AbbVie projects the two drugs will generate more than $31 billion in combined revenue by 2027, split roughly $20 billion from Skyrizi and $11 billion from Rinvoq.9Fierce Pharma. AbbVie Jacks 2027 Sales Projection for Skyrizi and Rinvoq to $31B Rinvoq alone brought in $5.97 billion globally in 2024,10AbbVie. AbbVie Full Year 2024 Financial Results and in Q1 2026 it contributed $2.12 billion, up 20% year over year, prompting AbbVie to raise its 2026 Rinvoq expectation to roughly $10.2 billion.11AbbVie. AbbVie Reports First Quarter 2026 Financial Results
Push the generic threat out four years and that revenue curve gets much longer. The FDA has approved Rinvoq for nine indications so far, most recently giant cell arteritis and polyarticular juvenile idiopathic arthritis in April 2025,12AbbVie. Rinvoq Receives US FDA Approval for Giant Cell Arteritis and in October 2025 the agency broadened the label for ulcerative colitis and Crohn’s disease, opening the drug to a wider patient pool.13AbbVie. FDA Approves Updated Indication Statement for Rinvoq for the Treatment of Inflammatory Bowel Disease Phase 3 trials in alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo are ongoing, each a potential new revenue stream under brand pricing for years longer than the market previously expected.
How Wall Street Repriced the Stock
William Blair analyst Matt Phipps called the settlement a “positive development” and said his firm had previously modeled a 2033 loss of exclusivity. With the four-year extension, Phipps said Rinvoq’s peak sales projections, already forecast at $19 billion globally and $15 billion in the U.S., “could now go even higher.”14Pharmaceutical Technology. AbbVie Extends Rinvoq Exclusivity by Four Years After Generics Settlements He also flagged potential new indications that could add roughly $2 billion to peak-year sales.15Pharmaceutical Executive. AbbVie Stock Jumps Following Settlement of Litigation With Drug Manufacturers Over Rinvoq
Other firms moved their targets in the days that followed:
- Leerink Partners raised its price target to $243 from $210 and kept an Outperform rating, citing Rinvoq’s extended exclusivity and Skyrizi’s 43% year-over-year growth in recent prescription data.
- BMO Capital raised its target to $240 from $215, maintaining Outperform.
- Piper Sandler reiterated Overweight with a $231 price target.
- Berenberg upgraded AbbVie from Hold to Buy, pointing to the company’s transition away from Humira.16Investing.com. AbbVie Price Target Raised to 243 From 210 at Leerink on Rinvoq Settlement
The Safety Ceiling That Doesn’t Go Away
Longer exclusivity does not remove Rinvoq’s competitive drag. As a JAK inhibitor, the drug carries an FDA black box warning, the agency’s most serious safety label, flagging increased risks of serious infections, cardiovascular events, blood clots, cancer, and death. The FDA imposed those warnings in early 2022 based on safety concerns across the JAK inhibitor class and, at the same time, limited all approved uses of Rinvoq to patients who have not responded to or cannot tolerate TNF blockers.17FDA. FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death That restriction makes Rinvoq a second-line treatment in most of its approved indications and caps the eligible patient population. The broadened IBD label in October 2025 eased that constraint somewhat, but the safety profile remains a competitive disadvantage relative to drugs without the same warnings.